Related Experiment Videos
CT, RECIST, and malignant pleural mesothelioma
1Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009 Australia. anowak@cyllene.uwa.edu.au
Lung Cancer (Amsterdam, Netherlands)
|June 14, 2005
Summary
Assessing malignant pleural mesothelioma (MPM) tumor response is challenging. Modified RECIST criteria offer improved uni-dimensional measurement for clinical trials, overcoming limitations of previous assessment standards.
Area of Science:
- Oncology
- Radiology
- Clinical Trials
Background:
- Malignant pleural mesothelioma (MPM) exhibits a unique growth pattern complicating treatment response assessment.
- Accurate tumor response evaluation is crucial for patient benefit, especially in Phase II clinical trials.
- Existing WHO and RECIST criteria are not optimally suited for MPM tumor measurement.
Purpose of the Study:
- To discuss uni-dimensional measurement of tumor response in pleural mesothelioma.
- To present the development and validation of modified RECIST criteria specifically for MPM.
- To address the shortcomings of standard RECIST criteria in the context of MPM.
Main Methods:
- Review of uni-dimensional measurement techniques for pleural mesothelioma.
- Development of modified RECIST criteria tailored for MPM.
- Validation of the modified RECIST criteria in clinical settings.
Main Results:
- Uni-dimensional measurement provides a feasible approach for MPM response assessment.
- Modified RECIST criteria demonstrate improved suitability for MPM compared to standard RECIST.
- The modified criteria aim to enhance the accuracy of tumor response evaluation in MPM.
Conclusions:
- Standard RECIST criteria have limitations for assessing MPM tumor response.
- Modified RECIST criteria offer a more appropriate method for evaluating treatment efficacy in MPM.
- These modified criteria can improve the reliability of clinical trial outcomes for MPM patients.